本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026 年 1 月 21 日 (二)股东会召开的地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 447 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 197,779,899 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 | 42.6932 | | 比例（%） | | 证券代码：603882 证券简称：金域医学 公告编号：2026-009 广州金域医学检验集团股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会召集，公司董事长梁耀铭先生主持，本次会议的召集、召 开及表决形式均符合《公司法》及《公司章程》的规定。 (五)公司 ...

北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2026 年第一次临时股东会的 法律意见书 二〇二六年一月 北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2026 年第一次临时股东会的 法律意见书 致：广州金域医学检验集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为广州金域医学检验集团股 份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席 公司 2026 年第一次临时股东会（以下简称"本次股东会"）。本所律师根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）等有关法律、法规、规范性文件及《广州金域医学检验集团股份有限 公司章程》（以下简称"《公司章程》"）的规定，对本次股东会进行见证并出 具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为作为出具本法律意见书 所必需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真实、 准确、完整的要求，有关副 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) is promoting the transformation of precision medicine, leading to a strong performance in the medical sector of both A-shares and Hong Kong stocks on January 21 [1][7]. Group 1: Market Performance - In the Hong Kong market, MicroPort Scientific Corporation (MicroPort) surged over 12%, leading the gains, while Alibaba Health increased by over 3% [1][7]. - The Hong Kong medical ETF, Huabao (159137), reached a peak of 1.78% during trading [1][7]. - A-shares also saw a recovery, with Meiyuan Health and Kingmed Diagnostics rising over 3%, and Yuyue Medical and Yingke Medical both increasing over 2% [3][9]. Group 2: ETF Insights - The largest medical ETF in the market (512170) rose over 1.3%, recovering its six-month moving average, with significant capital inflow of over 270 million yuan in net subscriptions [3][9]. - As of January 20, 2026, the medical ETF fund size is 26 billion yuan, making it the largest among medical ETFs in the market [5][11]. Group 3: Policy Developments - The NHSA issued the "Guidelines for the Pricing of Surgical and Treatment Auxiliary Medical Services (Trial)," standardizing pricing for robotic surgeries and remote surgical assistance [5][11]. - The guidelines include 37 pricing items, 5 additional charges, and 1 expansion item, covering various fields such as 3D reconstruction and remote surgery [5][11]. - Notable highlights in pathology services include the establishment of a separate pricing item for pathology diagnosis and the inclusion of digital pathology slice storage in the pricing structure [5][11].

Group 1 - The core viewpoint of the news is that Kingmed Diagnostics experienced a significant drop in stock price, with a decline of 9.37% on January 16, resulting in a trading volume of 1.084 billion yuan [1] - On January 16, Kingmed Diagnostics had a financing buy-in amount of 100 million yuan, with a net financing buy of -14.32 million yuan, indicating a higher level of financing activity compared to the past year [1] - The total financing and securities balance for Kingmed Diagnostics as of January 16 is 530 million yuan, which accounts for 3.53% of its market capitalization, indicating a high financing balance relative to historical levels [1] Group 2 - Kingmed Diagnostics provides a wide range of medical testing services, including nearly 80 types of testing technologies and approximately 3,200 testing projects to over 23,000 medical institutions across China [2] - The company's main business revenue composition includes 91.20% from medical diagnostic services, 6.45% from sales of diagnostics, and smaller contributions from other services [2] - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, reflecting a year-on-year decrease of 19.23%, and a net profit attributable to shareholders of -79.6095 million yuan, a decline of 184.84% [2] Group 3 - Since its A-share listing, Kingmed Diagnostics has distributed a total of 2.545 billion yuan in dividends, with 1.647 billion yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders of Kingmed Diagnostics include Hong Kong Central Clearing Limited as the second-largest shareholder, holding 35.5057 million shares, a decrease of 2.8676 million shares from the previous period [3] - The investment fund "Zhaoshang Advantage Enterprise Mixed A" has exited the list of the top ten circulating shareholders [3]

Key Points Summary of 金域医学 Conference Call Company Overview - **Company**: 金域医学 (Kingmed Diagnostics) - **Industry**: Medical Diagnostics and AI in Healthcare Core Insights and Arguments - **AI Medical Model Launch**: 金域医学 launched China's first medical testing industry AI model "小医医", serving over 370,000 doctors with nearly 200,000 active users, indicating its leadership in AI healthcare [2][3] - **Digital Transformation**: The company is actively exploring digital transformation to enhance operational efficiency and develop new business growth points, collaborating with hospitals like 中山三院 and local health authorities [2][5] - **Market Potential**: The AI healthcare market is projected to reach 5-6 trillion RMB, with revenue from AI and data-related businesses expected to exceed 100 million RMB from May to December 2025, and a forecasted revenue range of 50 million to 200 million RMB for 2026 [2][3] - **Strategic Partnerships**: Collaborations with hospitals and pharmaceutical companies are crucial, with hospitals being the main revenue source and pharmaceutical partnerships providing higher profit margins [11][12] Financial Performance and Projections - **Data as Core Asset**: In 2025, data revenue accounted for nearly 30% of total income, with a significantly higher profit margin compared to other AI-related businesses [3][17] - **Profitability Goals**: The company aims for a net profit margin of 6% to 8% in the short term, with strategies to improve efficiency and reduce costs amid hospital fee control pressures [3][20] - **Revenue Growth**: Expected positive revenue growth in 2026, with a focus on expanding into the pharmaceutical market to complement hospital business [20][11] Industry Dynamics - **Government Strategy**: The Chinese government aims for a 70% AI coverage in medical institutions by 2027, indicating strong demand for AI solutions in healthcare [7] - **Market Spending Trends**: Information technology spending in hospitals is expected to rise from 3% to 5% of revenue in the AI era, with the overall healthcare market potentially reaching 5-6 trillion RMB [9][10] - **Cost Control Trends**: Ongoing pressure on hospital testing fees is expected, with strategies in place to enhance efficiency and reduce costs through centralized procurement and digital transformation [19][24] Future Directions - **Product Development**: A detailed product line plan for 2026 includes quarterly releases of new products tailored to various hospital needs, focusing on standardized products and specialized AI applications [13] - **Collaboration Expansion**: Plans to increase partnerships with over 30 pharmaceutical companies, emphasizing the importance of high-quality data and rapid delivery [18][11] - **Focus on Smart Healthcare**: The company aims to become a preferred partner in smart healthcare, leveraging accumulated data and AI technology to support hospitals and related industries [6][28] Additional Important Insights - **Revenue from AI Products**: Hospital demand for AI products varies, with project costs typically ranging from 500,000 to 1 million RMB, and diverse pricing models including one-time fees and revenue-sharing [10] - **Impact of AI Models**: The "遇见医眼" and "小医医" models are foundational for AI applications, with plans to enhance their capabilities for both doctors and patients [15][16] - **Market Trends**: The trend towards outsourcing in large hospitals is expected to grow, driven by cost awareness and improved policy environments, which may lead to rapid revenue increases [24]

Group 1 - The core point of the news is that Kingmed Diagnostics experienced a decline of 5.34% in its stock price, reaching 34.05 CNY per share, with a trading volume of 279 million CNY and a turnover rate of 1.73%, resulting in a total market capitalization of 15.774 billion CNY [1] - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, is located in Guangzhou, Guangdong Province, and provides a wide range of diagnostic services to over 23,000 medical institutions across China [1] - The company's main business revenue composition includes medical diagnostic services at 91.20%, sales of diagnostics at 6.45%, other services at 1.47%, cold chain logistics at 0.62%, and health check-up services at 0.27% [1] Group 2 - From the perspective of major fund holdings, one fund under Great Wall Fund has a significant position in Kingmed Diagnostics, with Great Wall Consumer Value Mixed A (200006) reducing its holdings by 1.3 million shares in the third quarter, now holding 1.3005 million shares, which accounts for 4.58% of the fund's net value [2] - The fund has reported a floating loss of approximately 2.497 million CNY as of the latest update [2] - Great Wall Consumer Value Mixed A (200006) was established on April 6, 2006, with a current scale of 516 million CNY, and has achieved a year-to-date return of 21.73%, ranking 56 out of 8,847 in its category [2]

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [5]. Core Insights - The medical device industry in China has a prominent supply chain advantage, with overseas markets expected to maintain rapid growth. The brain-computer interface (BCI) sector is at a critical turning point, likely to see demand release. AI medical applications are gradually becoming operational, poised to reshape the health market [3]. Summary by Relevant Sections Investment Recommendations - For the overseas medical device sector, recommended stocks include: United Imaging Healthcare, Nanwei Medical, Microelectronic Physiology, Guichuang Tongqiao, Yuyue Medical, and New Industry. Stocks to watch include: Jingfeng Medical, MicroPort Scientific, and Chuangli Medical [5]. - In the brain-computer interface sector, recommended stocks are: Lepu Medical, Weisi Medical. Stocks to watch include: Meihao Medical, Xiangyu Medical, Mcland, Xinwei Medical, Aipeng Medical, Chengyitong, Chuangxin Medical, and Botuo Bio [5]. - For the AI + device sector, recommended stocks are: Yuyue Medical, BGI Genomics, KingMed Diagnostics, and United Imaging Healthcare. Stocks to watch include: Dian Diagnostics [5]. Overseas Market Growth - The supply chain advantage of domestic medical devices is significant, with exports expected to grow rapidly. In the first three quarters of 2025, United Imaging Healthcare's overseas revenue increased by 41.97% year-on-year, becoming a crucial growth driver for the company. The company continues to expand its market share in key regions due to superior product performance and localized service capabilities. By December 2025, MicroPort Scientific's global cumulative order volume exceeded 160 units, with core products in endoscopy, orthopedics, and vascular intervention surpassing 230 units in total orders. In 2025, Jingfeng Medical achieved a breakthrough in multiple key global markets, leading to explosive growth in overseas orders [5]. Brain-Computer Interface Market - The brain-computer interface market is at a pivotal turning point, with anticipated demand release. China's "14th Five-Year Plan" explicitly suggests a forward-looking layout for future industries, promoting BCI as a new economic growth point. In December 2025, Elon Musk announced that Neuralink would begin large-scale production of BCI devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process. In January 2026, China's BCI company Strong Brain Technology announced it had completed a new round of financing of approximately 2 billion yuan, setting a record for the second-largest single financing in the field globally, following Neuralink. The funds will be used to accelerate core technology research and development, extreme engineering breakthroughs, and product scaling and mass production [5]. AI Medical Applications - AI medical applications are gradually becoming operational, with the potential to reshape the health market. In June 2025, Ant Group launched the AI Health Manager AQ, which was officially upgraded to "Antifufu" in December 2025. By January 2026, the "Antifufu" app had over 30 million monthly active users, with daily inquiries exceeding 10 million, 55% of which came from third-tier cities and below. In January 2026, Tempus AI reported preliminary revenue of approximately 1.27 billion USD for 2025, representing an 83% year-on-year increase, exceeding initial expectations. OpenAI announced the acquisition of the healthcare tech startup Torch to expand into the healthcare sector, while Google launched the next-generation open-source medical AI model MedGemma1.5 and released the open-source medical speech-to-text model MedASR [5].

Core Insights - The integration of artificial intelligence in grassroots healthcare is seen as a new pathway to enhance the construction of county-level medical communities and address capability shortcomings [1][2] Group 1: AI Platform Launch - The launch of the AI-assisted diagnostic platform in Fengkai County, Guangdong, marks the establishment of the first county-level AI healthcare platform in the province, aimed at improving access to quality medical resources [1] - The platform will connect 19 county hospitals and township health centers, creating a model for "smart healthcare" that can be quantified, replicated, and promoted across the province and nation [1][2] Group 2: Data Sharing and Integration - The platform focuses on building a "data sharing hub" to connect hospitals and grassroots testing and pathology information systems, enhancing regional medical service capabilities [2] - Gold Domain Medical, as a co-builder of the regional testing and pathology center, is integrating medical data from county and township institutions into a centralized management platform [2] Group 3: AI Applications in Healthcare - The platform will utilize Gold Domain Medical's proprietary AI models and applications to embed intelligent features into hospital workflows, providing clinical doctors with tools for report interpretation, project evaluation, and medication assistance [3] - The integration of AI tools aims to significantly enhance the convenience of diagnosis and treatment processes for healthcare providers [3] Group 4: Strategic Goals and Future Plans - The establishment of the AI-assisted diagnostic platform is a key initiative for Fengkai County to implement the "Healthy China" strategy and the "Hundred Counties, Thousand Towns, and Ten Thousand Villages" project [3] - Future plans include the creation of a "Gold Domain-Fengkai Medical AI Research Training Center" to enhance the understanding and application of AI tools among regional medical personnel [3]

Group 1 - The A-share market saw all three major indices rise, with the medical device ETF (562600) increasing by 2.30% in early trading [1] - AI applications in the medical sector continued to perform strongly, with notable stock increases: Dean Diagnostics surged by 12.48%, Yuyue Medical rose by 9.10%, Tianzhihang increased by 6.99%, and Kingmed Diagnostics went up by 5.02% [1] - The medical device ETF (562600) has attracted significant capital, with a net inflow of 91 million yuan over the past five days and a trading volume of 26.96 million yuan at the time of reporting [1] Group 2 - OpenAI has invested $60 million to acquire the medical technology startup Torch, enhancing its AI healthcare strategy. The acquisition focuses on developing a "unified medical memory" system to integrate disparate patient health data [1] - The medical device industry is experiencing robust growth, with the medical device ETF (562600) tracking the CSI All Index for medical devices, which has a 23.8% allocation to brain-computer interface stocks, the highest among listed ETFs [2] - The ETF's high concentration in the medical device sector, at 89.2%, allows for effective capture of growth opportunities in niche markets [2]

Core Viewpoint - The company, Guangzhou Kingmed Diagnostics Group Co., Ltd., anticipates a net loss for the fiscal year 2025, primarily due to extended collection periods for accounts receivable leading to significant credit impairment losses [1]. Financial Performance - The company expects the net profit attributable to shareholders for 2025 to be negative, indicating an operational loss for the year [1]. - The final financial data will be disclosed in the official 2025 annual report, which will provide the confirmed figures [1]. Compliance and Disclosure - The company commits to adhering to the Shanghai Stock Exchange listing rules and will expedite its financial accounting processes to release the 2025 annual performance forecast promptly [1]. - Designated media for information disclosure includes China Securities Journal, Shanghai Securities Journal, Securities Times, Securities Daily, and the Shanghai Stock Exchange website [1].